Loading clinical trials...

Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV

Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, and Efficacy of RV521 in the Treatment of Adult Subjects Who Have Undergone Hematopoietic Cell Transplantation (HCT) With a Documented Upper Respiratory Tract Infection (URTI) With Respiratory Syncytial Virus (RSV)

NCT04267822•Pfizer

View on ClinicalTrials.gov

Summary

RV521 is to being developed to treat RSV infection and disease in susceptible individuals at high risk for complications. This is an international, multicenter, placebo-controlled study. Eligible subjects are adults with a documented symptomatic RSV infection who have undergone HCT transplantation and are moderately to severely immunocompromised. Qualified subjects will be randomized in a 1:1 ratio to receive RV521 or placebo, twice daily for 10 days.

Detailed Description

The purpose of this study is to compare the viral load, safety, tolerability, and clinical efficacy of RV521 compared to placebo. This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled study. Up to 200 adult subjects with a documented symptomatic RSV URTI who have undergone HCT within 1 year of randomization and who are moderately to severely immunocompromised will be randomized. Qualified subjects will be randomized in a 1:1 ratio to receive RV521 capsules or matching placebo twice daily for 10 days. After the completion of the 10-day double-blind treatment period, subjects will be followed for an additional 28 days. Study drug may be taken on an outpatient or inpatient basis, depending on clinical status and site practices. Randomization will be stratified by type of HCT graft and ALC count. There are 9 clinic visits planned for this study.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Diagnosed with Chronic Graft-vs-Host Disease (GVHD), or
•2. Has used systemic corticosteroids in the 30 days prior to RSV infection
•2. Has moderate to severe immunocompromise, defined as a score ≥ 5 on the ISI-RSV and/or an ALC of ≤ 500 cells/ mm3
•3. Documentation of positive RSV infection in the upper airway

Exclusion Criteria

•1. Use of non-marketed investigational agents within 30 days, OR use of an investigational monoclonal anti-RSV antibodies within 4 months or 5 half-lives of screening, whichever is longer, OR use of any investigational RSV vaccines after HCT.
•2. Receiving a prescription, OTC, or herbal medication that is a potent inducer or inhibitor of CYP3A4, within 2 weeks of Randomization.
•3. Receiving a prescription, OTC, or herbal medication that is a substrate of CYP3A4 with a narrow therapeutic index where monitoring blood levels is not possible.
•4. Known chronic infection with hepatitis B, C, or HIV.
•5. Is in the pre-engraftment period during RSV infection.
•6. Admitted to the hospital primarily for lower respiratory tract disease of any cause as determined by the Investigator.
•7. Any condition requiring mechanical ventilation or vasopressor support at the time of randomization.
•8. Clinically significant bacteremia or fungemia within 5 days prior to Screening that has not been adequately treated.
•9. Clinically significant bacterial, fungal, or viral pneumonia within 2 weeks prior to Screening that has not been adequately treated.
•10. Excessive nausea/vomiting at Screening or an inability to swallow capsules.
+1 more criteria

Key Dates

Start Date

June 15, 2020

Primary Completion Date

June 30, 2023

Completion Date

July 31, 2023

Last Updated

May 8, 2023

Conditions

RSV InfectionStem Cell Transplant ComplicationsLower Resp Tract Infection

Interventions

RV521 oral tablet

DRUG

Placebo oral tablet

DRUG

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

NCT03394365

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant Complications+3 more

View study

RECRUITINGNA

Modified Second Haplo-transplantation for Graft Failure

NCT06512545

Graft FailureStem Cell Transplant Complications

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 8, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV

Inclusion Criteria

Exclusion Criteria

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Modified Second Haplo-transplantation for Graft Failure

Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT

Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT

Delirium in Children Undergoing Stem Cell Transplantation

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children